Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : Australian judge finds Johnson & Johnson 'negligent' in vaginal mesh lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/21/2019 | 03:38pm EST

A federal court in Australia found Johnson & Johnson and its subsidiary Ethicon liable Thursday in class-action lawsuit after a seven-year legal battle over flawed vaginal mesh implants.

More than 1,000 women registered to take part in the class action beginning in October 2012, with the trial beginning in federal court in 2017 involving 700 Australian patients.

The verdict means those harmed could be compensated, but that amount will not be finalized until next year, ABC Radio News reported. Johnson & Johnson is considering whether to appeal the verdict.

Three women who led the class action were heard from in federal court, including Kathryn Gill, Diane Dawson and Ann Sanders. Gill described the pain she experienced from the implant as "so bad she struggles to breathe." Dawson referred to the same as "excruciating." And Sanders said it felt like "there was a blade in her vagina."

The vaginal mesh devices were implanted to treat pelvic prolapse, urinary incontinence or other complications of child birth, but women said they suffered emotionally, mentally and physically with severe, debilitating and chronic pain, and have been unable to have intercourse.

In many cases, the mesh eroded internally, causing infections, multiple complications, and was nearly impossible to completely remove, testimony showed.

Defendants had suggested that complications were rare, but Justice Anna Katzmann rejected that suggestion.

"I was satisfied that a number of the pleaded complications are not uncommon, and some in fact are common," she said.

The judge said that the company and its product development arm Ethicon were "negligent," downplaying the risks of the product, which was not tested properly, while rushing the product to market.

"The devices were not tested properly and those selling them knew they did not have sufficient data to show they were safe," Katzmann said.

One of the claimants, Julie Davis, said that the verdict was a step in the right direction.

Ethicon defended its practices, saying in a statement, "Ethicon believes that the company acted ethically and responsibly in the research, development and supply of these products."

Around 8,000 women in Australia and 100,000 worldwide have been estimated to have used the implants.

Last month, Johnson & Johnson and Ethicon reached a settlement of about $117 million in the United States for alleged misleading marketing of the vaginal mesh implants.

Copyright 2019 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source International Top News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
11:41aJOHNSON & JOHNSON : Janssen to Acquire Investigational Bermekimab from XBiotech
PU
10:38aXBiotech Shares Jump After Selling Bermekimab to Janssen
DJ
08:17aJOHNSON & JOHNSON : Janssen Pharmaceutical Companies - IMBRUVICA Combination The..
AQ
08:17aJOHNSON & JOHNSON : Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. F..
AQ
06:52aJOHNSON & JOHNSON : Announces Commitment to Support Republic of Rwanda's Prepare..
AQ
06:41aXBIOTECH : Sells Bermekimad to Janssen Biotech
DJ
12/06JOHNSON & JOHNSON : Janssen Says Investigational Treatment for Myeloma Gets FDA ..
DJ
12/06AMGEN : Says FDA Approves Avsola for Same Indications as Remicade
DJ
12/05JOHNSON & JOHNSON : Change in Directors or Principal Officers (form 8-K)
AQ
12/05JOHNSON & JOHNSON : Names Hubert Joly, Executive Chairman of Best Buy and Mark A..
PU
More news
Financials (USD)
Sales 2019 82 175 M
EBIT 2019 25 638 M
Net income 2019 17 334 M
Debt 2019 6 823 M
Yield 2019 2,68%
P/E ratio 2019 21,5x
P/E ratio 2020 18,9x
EV / Sales2019 4,58x
EV / Sales2020 4,30x
Capitalization 369 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 149,80  $
Last Close Price 140,38  $
Spread / Highest target 23,2%
Spread / Average Target 6,71%
Spread / Lowest Target -8,11%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS22.87%208 547
BRISTOL-MYERS SQUIBB COMPANY15.33%140 534